Gut-Selective Design of Orally Administered Izencitinib (TD-1473) Limits Systemic Exposure and Effects of Janus Kinase Inhibition in Nonclinical Species

Izencitinib (TD-1473), an oral, gut-selective pan-Janus kinase (JAK) inhibitor under investigation for treatment of inflammatory bowel diseases, was designed for optimal efficacy in the gastrointestinal tract while minimizing systemic exposures and JAK-related safety findings. The nonclinical safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Hardwick, Rhiannon N, Brassil, Patrick, Badagnani, Ilaria, Perkins, Kimberly, Obedencio, Glenmar P, Kim, Andrea S, Conner, Michael W, Bourdet, David L, Harstad, Eric B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Regulatory Science, Risk Assessment, and Decision Making
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963331/
https://www.ncbi.nlm.nih.gov/pubmed/35134999
http://dx.doi.org/10.1093/toxsci/kfac002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963331/
https://www.ncbi.nlm.nih.gov/pubmed/35134999
http://dx.doi.org/10.1093/toxsci/kfac002

Ejemplares similares